Western Regional Blog – BC, YK, AB, NWT and Nunavut
Purpose: Enzastaurin is an oral serine/threonine kinase inhibitor antitumor agent. Our phase II trial tested the efficacy and safety of enzastaurin added to a standard carboplatin/paclitaxel chemotherapy regimen in patients with newly diagnosed advanced ovarian cancer.
Patients and Methods: This was a randomized, placebo-controlled study in patients with International Federation of Gynecology and Obstetrics stage IIB to IV ovarian, fallopian tube, or peritoneal epithelial carcinoma. Patients were randomly assigned to six cycles of chemotherapy (paclitaxel/carboplatin ± enzastaurin [PCE/PC]) followed by maintenance therapy (enzastaurin/placebo). Primary end point was progression-free survival (PFS). Secondary measures included response rate, safety assessment, and translational research.
Results: HR, 0.51; 95% CI, 0.30 to 0.85; P = .009). HR for covariate stage (stage IIB to IIIB v IIIC to IV) was not statistically significant (0.75; 95% CI, 0.38 to 1.47; P = .40). Translational research of immunohistochemistry protein assays did not identify any markers significantly associated with treatment difference regarding PFS.
Conclusion: The PCE combination increased PFS, but it was not significantly superior to PC in this phase II study.
J. Clin. Oncol. 2013 Jul 29;[EPub Ahead of Print], IB Vergote, R Chekerov, F Amant, P Harter, A Casado, J Emerich, T Bauknecht, K Mansouri, SP Myrand, TS Nguyen, P Shi, J Sehouli